Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| LUMOS PHARMA, INC.(NLNK) · Entity 85102 | Director | May 23, 2018 | May 25, 2018 |
| Replimune Group, Inc.REPL · Entity 4707 | Director | April 01, 2026 | April 08, 2026 |
| WEST PHARMACEUTICAL SERVICES INCWST · Entity 3201 | Director | May 04, 2026 | May 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
LUMOS PHARMA, INC.
Report date May 23, 2018 · Filed May 25, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.33 · Expires 2028-05-22 | Direct | 27,777 |
Reported balance
After 2018-05-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-05-23 · Grant · Acquired 27,777 · Balance 27,777 F1: Automatic grant to the Reporting Person of a nonstatutory stock option under the Issuer's 2009 Equity Incentive Plan (the "Plan"). One hundred percent (100%) of the shares shall vest on the earlier of (i) the first anniversary of the date of grant and (ii) the date of the first Annual Meeting following the date of grant, in each case subject to the Reporting Person's continuous service as of such date. The option expires ten years after the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Automatic grant to the Reporting Person of a nonstatutory stock option under the Issuer's 2009 Equity Incentive Plan (the "Plan"). One hundred percent (100%) of the shares shall vest on the earlier of (i) the first anniversary of the date of grant and (ii) the date of the first Annual Meeting following the date of grant, in each case subject to the Reporting Person's continuous service as of such date. The option expires ten years after the date of grant.
Replimune Group, Inc.
Report date April 01, 2026 · Filed April 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.61 · Expires 2036-04-01 | Direct | 44,500 |
Reported balance
After 2026-04-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-04-01 · Grant · Acquired 44,500 · Balance 44,500 F1: The shares underlying this option vest entirely on April 1, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this option vest entirely on April 1, 2027.
WEST PHARMACEUTICAL SERVICES INC
Report date May 04, 2026 · Filed May 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 11,854.297 |
Reported balance
After 2026-05-04 transaction · row 1
1 source rowRow 1 · 2026-05-04 · Grant · Acquired 791 · Balance 11,854.297 F1: These shares of restricted stock units will vest in full on the date of the next annual shareholder meeting and will be distributable under the terms of the Deferred Compensation Plan for Outside Directors. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares of restricted stock units will vest in full on the date of the next annual shareholder meeting and will be distributable under the terms of the Deferred Compensation Plan for Outside Directors.
Past disclosures · reporting ended (3)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ARQULE INC
Report date January 16, 2020 · Filed January 16, 2020
Section 16 reporting ended · disclosed 2020-01-16. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-01-16 transaction · row 1
1 source rowRow 1 · 2020-01-16 · Other · Disposed 1,235,782 · Balance 0 F1: On December 6, 2019, ArQule, Inc. (the "Company") entered into an Agreement and Plan of Merger (as amended, supplemented or otherwise modified from time to time, the "Merger Agreement") with Merck Sharpe & Dohme Corp. ("MSD") and Argon Merger Sub, Inc., a wholly-owned subsidiary of MSD ("Merger Sub"), pursuant to which MSD acquired the Company by a tender offer for all shares of Company common stock (the "Offer") and a subsequent merger (the "Merger"), each of which became effective on January 16, 2020. Pursuant to the Merger Agreement, (i) Merger Sub purchased all shares of Company common stock that were validly tendered pursuant to the Offer for a cash payment equal to $20.00 per share (the "Offer Price") and (ii) all shares of Company common stock outstanding immediately prior to the effective time of the Merger (the "Effective Time"), were cancelled and converted automatically into the right to receive the Offer Price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.16 · Expires 2025-01-20 | Direct | 0 |
Reported balance
After 2020-01-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-01-16 · Disposition to issuer · Disposed 242,502 · Balance 0 F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.79 · Expires 2026-01-19 | Direct | 0 |
Reported balance
After 2020-01-16 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-01-16 · Disposition to issuer · Disposed 120,000 · Balance 0 F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.53 · Expires 2027-01-17 | Direct | 0 |
Reported balance
After 2020-01-16 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-01-16 · Disposition to issuer · Disposed 300,000 · Balance 0 F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.95 · Expires 2027-04-04 | Direct | 0 |
Reported balance
After 2020-01-16 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-01-16 · Disposition to issuer · Disposed 600,000 · Balance 0 F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.75 · Expires 2028-01-16 | Direct | 0 |
Reported balance
After 2020-01-16 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2020-01-16 · Disposition to issuer · Disposed 249,000 · Balance 0 F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.48 · Expires 2028-05-08 | Direct | 0 |
Reported balance
After 2020-01-16 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2020-01-16 · Disposition to issuer · Disposed 80,000 · Balance 0 F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.48 · Expires 2028-07-23 | Direct | 0 |
Reported balance
After 2020-01-16 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2020-01-16 · Disposition to issuer · Disposed 150,000 · Balance 0 F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.68 · Expires 2029-01-15 | Direct | 0 |
Reported balance
After 2020-01-16 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2020-01-16 · Disposition to issuer · Disposed 650,850 · Balance 0 F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.14 · Expires 2020-07-15 | Direct | 0 |
Reported balance
After 2020-01-16 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2020-01-16 · Disposition to issuer · Disposed 100,000 · Balance 0 F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.70 · Expires 2021-01-24 | Direct | 0 |
Reported balance
After 2020-01-16 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2020-01-16 · Disposition to issuer · Disposed 14,925 · Balance 0 F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.95 · Expires 2022-02-01 | Direct | 0 |
Reported balance
After 2020-01-16 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2020-01-16 · Disposition to issuer · Disposed 7,578 · Balance 0 F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.51 · Expires 2023-01-14 | Direct | 0 |
Reported balance
After 2020-01-16 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2020-01-16 · Disposition to issuer · Disposed 285,000 · Balance 0 F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.57 · Expires 2024-01-22 | Direct | 0 |
Reported balance
After 2020-01-16 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2020-01-16 · Disposition to issuer · Disposed 305,000 · Balance 0 F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: On December 6, 2019, ArQule, Inc. (the "Company") entered into an Agreement and Plan of Merger (as amended, supplemented or otherwise modified from time to time, the "Merger Agreement") with Merck Sharpe & Dohme Corp. ("MSD") and Argon Merger Sub, Inc., a wholly-owned subsidiary of MSD ("Merger Sub"), pursuant to which MSD acquired the Company by a tender offer for all shares of Company common stock (the "Offer") and a subsequent merger (the "Merger"), each of which became effective on January 16, 2020. Pursuant to the Merger Agreement, (i) Merger Sub purchased all shares of Company common stock that were validly tendered pursuant to the Offer for a cash payment equal to $20.00 per share (the "Offer Price") and (ii) all shares of Company common stock outstanding immediately prior to the effective time of the Merger (the "Effective Time"), were cancelled and converted automatically into the right to receive the Offer Price.
F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration.
Merus N.V.
Report date December 12, 2025 · Filed December 12, 2025
Section 16 reporting ended · disclosed 2025-12-12. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $41.60 · Expires 2035-05-22 | Direct | 0 |
Reported balance
After 2025-12-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-12-12 · Disposition to issuer · Disposed 13,193 · Balance 0 F1: On September 29, 2025, Merus N.V. (the "Issuer") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the "Transaction Agreement") with Genmab A/S ("Genmab") and its wholly owned subsidiary, Genmab Holding II B.V. (the "Purchaser"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the "Shares"), of the Issuer (the "Offer"), and, on December 12, 2025 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time. F2: This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option. |
| Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $48.73 · Expires 2034-05-07 | Direct | 0 |
Reported balance
After 2025-12-12 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-12-12 · Disposition to issuer · Disposed 8,844 · Balance 0 F1: On September 29, 2025, Merus N.V. (the "Issuer") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the "Transaction Agreement") with Genmab A/S ("Genmab") and its wholly owned subsidiary, Genmab Holding II B.V. (the "Purchaser"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the "Shares"), of the Issuer (the "Offer"), and, on December 12, 2025 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time. F2: This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option. |
| Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.29 · Expires 2033-06-08 | Direct | 0 |
Reported balance
After 2025-12-12 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-12-12 · Disposition to issuer · Disposed 14,414 · Balance 0 F1: On September 29, 2025, Merus N.V. (the "Issuer") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the "Transaction Agreement") with Genmab A/S ("Genmab") and its wholly owned subsidiary, Genmab Holding II B.V. (the "Purchaser"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the "Shares"), of the Issuer (the "Offer"), and, on December 12, 2025 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time. F2: This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option. |
| Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.56 · Expires 2032-05-31 | Direct | 0 |
Reported balance
After 2025-12-12 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-12-12 · Disposition to issuer · Disposed 16,604 · Balance 0 F1: On September 29, 2025, Merus N.V. (the "Issuer") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the "Transaction Agreement") with Genmab A/S ("Genmab") and its wholly owned subsidiary, Genmab Holding II B.V. (the "Purchaser"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the "Shares"), of the Issuer (the "Offer"), and, on December 12, 2025 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time. F2: This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option. |
| Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.15 · Expires 2031-05-28 | Direct | 0 |
Reported balance
After 2025-12-12 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2025-12-12 · Disposition to issuer · Disposed 6,120 · Balance 0 F1: On September 29, 2025, Merus N.V. (the "Issuer") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the "Transaction Agreement") with Genmab A/S ("Genmab") and its wholly owned subsidiary, Genmab Holding II B.V. (the "Purchaser"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the "Shares"), of the Issuer (the "Offer"), and, on December 12, 2025 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time. F2: This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option. |
| Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.09 · Expires 2030-06-30 | Direct | 0 |
Reported balance
After 2025-12-12 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2025-12-12 · Disposition to issuer · Disposed 17,262 · Balance 0 F1: On September 29, 2025, Merus N.V. (the "Issuer") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the "Transaction Agreement") with Genmab A/S ("Genmab") and its wholly owned subsidiary, Genmab Holding II B.V. (the "Purchaser"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the "Shares"), of the Issuer (the "Offer"), and, on December 12, 2025 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time. F2: This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option. |
Filing footnotes · ownership attribution and instrument terms
F1: On September 29, 2025, Merus N.V. (the "Issuer") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the "Transaction Agreement") with Genmab A/S ("Genmab") and its wholly owned subsidiary, Genmab Holding II B.V. (the "Purchaser"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the "Shares"), of the Issuer (the "Offer"), and, on December 12, 2025 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time.
F2: This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option.
Trillium Therapeutics Inc.
Report date November 17, 2021 · Filed November 19, 2021
Section 16 reporting ended · disclosed 2021-11-19. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.50 · Expires 2030-11-15 | Direct | 0 |
Reported balance
After 2021-11-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-11-17 · Disposition to issuer · Disposed 67,000 · Balance 0 F1: On November 17, 2021 (the "Closing Date"), PF Argentum Acquisition ULC, an indirect wholly owned subsidiary of Pfizer, Inc. (the "Purchaser") acquired all of the outstanding common shares of Trillium Therapeutics Inc. (the "Issuer") under a plan of arrangement pursuant to the Canada Business Corporations Act (British Columbia) (the "Plan of Arrangement"), whereby Issuer became a wholly owned subsidiary of the Purchaser. At the Effective Time (the "Effective Time") of the Plan of Arrangement, all common shares and equity awards of the Issuer that were issued and outstanding immediately prior to the Effective Time were converted into the right to receive $18.50 per share in cash. |
Filing footnotes · ownership attribution and instrument terms
F1: On November 17, 2021 (the "Closing Date"), PF Argentum Acquisition ULC, an indirect wholly owned subsidiary of Pfizer, Inc. (the "Purchaser") acquired all of the outstanding common shares of Trillium Therapeutics Inc. (the "Issuer") under a plan of arrangement pursuant to the Canada Business Corporations Act (British Columbia) (the "Plan of Arrangement"), whereby Issuer became a wholly owned subsidiary of the Purchaser. At the Effective Time (the "Effective Time") of the Plan of Arrangement, all common shares and equity awards of the Issuer that were issued and outstanding immediately prior to the Effective Time were converted into the right to receive $18.50 per share in cash.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 04, 2026 Filed May 6, 2026 21:37 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantCommon Stock | 791 | $0.00 | $0.00 |
DisclosureSEC source: 0000105770-26-000066 · form4.xml · nonDerivative · entry 1 Pucci Paolo · CIK 0001436861 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,854.297 F1 · shares: These shares of restricted stock units will vest in full on the date of the next annual shareholder meeting and will be distributable under the terms of the Deferred Compensation Plan for Outside Directors. Read SEC document |
| April 01, 2026 Filed Apr 8, 2026 01:08 UTC | Replimune Group, Inc. REPL · Entity 4707 | GrantStock Option (right to buy) · Derivative | 44,500 | $0.00 Strike: $7.61 | $0.00 |
DisclosureSEC source: 0001104659-26-040569 · tm2611350-10_4seq1.xml · derivative · entry 1 Pucci Paolo · CIK 0001436861 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,500 Underlying: Common Stock · 44,500 shares Expires 2036-04-01 F1 · derivative.exercise_date: The shares underlying this option vest entirely on April 1, 2027. Read SEC document |
| December 12, 2025 Filed Dec 12, 2025 23:56 UTC | Merus N.V. MRUS · Entity 70740 | Disposition to issuerShare Option (right to buy) · Derivative | 17,262 | $0.00 Strike: $16.09 | $0.00 |
DisclosureSEC source: 0001193125-25-317942 · ownership.xml · derivative · entry 6 Pucci Paolo · CIK 0001436861 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 17,262 shares Expires 2030-06-30 F1 · derivative.exercise_date: On September 29, 2025, Merus N.V. (the "Issuer") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the "Transaction Agreement") with Genmab A/S ("Genmab") and its wholly owned subsidiary, Genmab Holding II B.V. (the "Purchaser"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the "Shares"), of the Issuer (the "Offer"), and, on December 12, 2025 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time. F2 · derivative.exercise_date: This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option. Read SEC document |
| December 12, 2025 Filed Dec 12, 2025 23:56 UTC | Merus N.V. MRUS · Entity 70740 | Disposition to issuerShare Option (right to buy) · Derivative | 6,120 | $0.00 Strike: $21.15 | $0.00 |
DisclosureSEC source: 0001193125-25-317942 · ownership.xml · derivative · entry 5 Pucci Paolo · CIK 0001436861 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 6,120 shares Expires 2031-05-28 F1 · derivative.exercise_date: On September 29, 2025, Merus N.V. (the "Issuer") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the "Transaction Agreement") with Genmab A/S ("Genmab") and its wholly owned subsidiary, Genmab Holding II B.V. (the "Purchaser"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the "Shares"), of the Issuer (the "Offer"), and, on December 12, 2025 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time. F2 · derivative.exercise_date: This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option. Read SEC document |
| December 12, 2025 Filed Dec 12, 2025 23:56 UTC | Merus N.V. MRUS · Entity 70740 | Disposition to issuerShare Option (right to buy) · Derivative | 16,604 | $0.00 Strike: $18.56 | $0.00 |
DisclosureSEC source: 0001193125-25-317942 · ownership.xml · derivative · entry 4 Pucci Paolo · CIK 0001436861 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 16,604 shares Expires 2032-05-31 F1 · derivative.exercise_date: On September 29, 2025, Merus N.V. (the "Issuer") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the "Transaction Agreement") with Genmab A/S ("Genmab") and its wholly owned subsidiary, Genmab Holding II B.V. (the "Purchaser"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the "Shares"), of the Issuer (the "Offer"), and, on December 12, 2025 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time. F2 · derivative.exercise_date: This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option. Read SEC document |
| December 12, 2025 Filed Dec 12, 2025 23:56 UTC | Merus N.V. MRUS · Entity 70740 | Disposition to issuerShare Option (right to buy) · Derivative | 14,414 | $0.00 Strike: $23.29 | $0.00 |
DisclosureSEC source: 0001193125-25-317942 · ownership.xml · derivative · entry 3 Pucci Paolo · CIK 0001436861 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 14,414 shares Expires 2033-06-08 F1 · derivative.exercise_date: On September 29, 2025, Merus N.V. (the "Issuer") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the "Transaction Agreement") with Genmab A/S ("Genmab") and its wholly owned subsidiary, Genmab Holding II B.V. (the "Purchaser"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the "Shares"), of the Issuer (the "Offer"), and, on December 12, 2025 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time. F2 · derivative.exercise_date: This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option. Read SEC document |
| December 12, 2025 Filed Dec 12, 2025 23:56 UTC | Merus N.V. MRUS · Entity 70740 | Disposition to issuerShare Option (right to buy) · Derivative | 8,844 | $0.00 Strike: $48.73 | $0.00 |
DisclosureSEC source: 0001193125-25-317942 · ownership.xml · derivative · entry 2 Pucci Paolo · CIK 0001436861 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 8,844 shares Expires 2034-05-07 F1 · derivative.exercise_date: On September 29, 2025, Merus N.V. (the "Issuer") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the "Transaction Agreement") with Genmab A/S ("Genmab") and its wholly owned subsidiary, Genmab Holding II B.V. (the "Purchaser"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the "Shares"), of the Issuer (the "Offer"), and, on December 12, 2025 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time. F2 · derivative.exercise_date: This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option. Read SEC document |
| December 12, 2025 Filed Dec 12, 2025 23:56 UTC | Merus N.V. MRUS · Entity 70740 | Disposition to issuerShare Option (right to buy) · Derivative | 13,193 | $0.00 Strike: $41.60 | $0.00 |
DisclosureSEC source: 0001193125-25-317942 · ownership.xml · derivative · entry 1 Pucci Paolo · CIK 0001436861 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 13,193 shares Expires 2035-05-22 F1 · derivative.exercise_date: On September 29, 2025, Merus N.V. (the "Issuer") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the "Transaction Agreement") with Genmab A/S ("Genmab") and its wholly owned subsidiary, Genmab Holding II B.V. (the "Purchaser"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the "Shares"), of the Issuer (the "Offer"), and, on December 12, 2025 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time. F2 · derivative.exercise_date: This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option. Read SEC document |
| May 22, 2025 Filed May 27, 2025 12:00 UTC | Merus N.V. MRUS · Entity 70740 | GrantShare Option (right to buy) · Derivative | 13,193 | $0.00 Strike: $41.60 | $0.00 |
DisclosureSEC source: 0000950170-25-077385 · ownership.xml · derivative · entry 1 Pucci Paolo · CIK 0001436861 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,193 Underlying: Common Shares · 13,193 shares Expires 2035-05-22 F1 · derivative.exercise_date: Options vest over a one-year period commencing on May 22, 2025 in 12 equal monthly installments. Read SEC document |
| May 06, 2025 Filed May 8, 2025 21:00 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantCommon Stock | 1,071 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-013724 · form4.xml · nonDerivative · entry 1 Pucci Paolo · CIK 0001436861 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,946.95 F1 · shares: These shares of restricted stock units will vest in full on the date of the next annual shareholder meeting and will be distributable under the terms of the Deferred Compensation Plan for Outside Directors. Read SEC document |
| April 01, 2025 Filed Apr 4, 2025 00:05 UTC | Replimune Group, Inc. REPL · Entity 4707 | GrantStock Option (right to buy) · Derivative | 32,000 | $0.00 Strike: $8.40 | $0.00 |
DisclosureSEC source: 0001104659-25-031834 · tm2511407-10_4seq1.xml · derivative · entry 1 Pucci Paolo · CIK 0001436861 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,000 Underlying: Common Stock · 32,000 shares Expires 2035-04-01 F1 · derivative.exercise_date: The shares underlying this option vest entirely on April 1, 2026. Read SEC document |
| May 07, 2024 Filed May 9, 2024 20:30 UTC | Merus N.V. MRUS · Entity 70740 | GrantShare Option (right to buy) · Derivative | 8,844 | $0.00 Strike: $48.73 | $0.00 |
DisclosureSEC source: 0000950170-24-057090 · ownership.xml · derivative · entry 1 Pucci Paolo · CIK 0001436861 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,844 Underlying: Common Shares · 8,844 shares Expires 2034-05-07 F1 · derivative.exercise_date: Options vest over a one-year period commencing May 7, 2024 in 12 equal monthly installments. Read SEC document |
| April 23, 2024 Filed Apr 25, 2024 20:55 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantCommon Stock | 564 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-013408 · form4.xml · nonDerivative · entry 1 Pucci Paolo · CIK 0001436861 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,875.95 F1 · shares: These shares of restricted stock units will vest in full at the next annual shareholder meeting and will be distributable under the terms of the Deferred Compensation Plan for Outside Directors. Read SEC document |
| April 01, 2024 Filed Apr 4, 2024 00:02 UTC | Replimune Group, Inc. REPL · Entity 4707 | GrantStock Option (right to buy) · Derivative | 32,000 | $0.00 Strike: $7.73 | $0.00 |
DisclosureSEC source: 0001104659-24-043257 · tm2410652-10_4seq1.xml · derivative · entry 1 Pucci Paolo · CIK 0001436861 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,000 Underlying: Common Stock · 32,000 shares Expires 2034-04-01 F1 · derivative.exercise_date: The shares underlying this option vest entirely on April 1, 2025. Read SEC document |
| June 08, 2023 Filed Jun 12, 2023 20:16 UTC | Merus N.V. MRUS · Entity 70740 | GrantShare option (right to buy) · Derivative | 14,414 | $0.00 Strike: $23.29 | $0.00 |
DisclosureSEC source: 0001209191-23-036273 · doc4.xml · derivative · entry 1 Pucci Paolo · CIK 0001436861 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,414 Underlying: Common Shares · 14,414 shares Expires 2033-06-08 F1 · derivative.exercise_date: Options vest over a one-year period commencing June 8, 2023 in 12 equal monthly installments. Read SEC document |
| April 25, 2023 Filed Apr 27, 2023 21:17 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantCommon Stock | 616 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001562180-23-003697 · primarydocument.xml · nonDerivative · entry 1 Pucci Paolo · CIK 0001436861 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,311.95 F1 · price: These shares of restricted stock units will vest in full on the first anniversary of the date of the grant and will be distributable under the terms of the Deferred Compensation Plan for Outside Directors. Read SEC document |
| April 01, 2023 Filed Apr 5, 2023 00:04 UTC | Replimune Group, Inc. REPL · Entity 4707 | GrantStock Option (right to buy) · Derivative | 25,200 | $0.00 Strike: $17.66 | $0.00 |
DisclosureSEC source: 0001104659-23-041735 · tm2311410-14_4seq1.xml · derivative · entry 1 Pucci Paolo · CIK 0001436861 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,200 Underlying: Common Stock · 25,200 shares Expires 2033-04-01 F1 · derivative.exercise_date: The shares underlying this option vest entirely on April 1, 2024. Read SEC document |
| May 31, 2022 Filed Jun 2, 2022 20:05 UTC | Merus N.V. MRUS · Entity 70740 | GrantShare option (right to buy) · Derivative | 16,604 | $0.00 Strike: $18.56 | $0.00 |
DisclosureSEC source: 0000899243-22-020670 · doc4.xml · derivative · entry 1 Pucci Paolo · CIK 0001436861 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,604 Underlying: Common Shares · 16,604 shares Expires 2032-05-31 F1 · derivative.exercise_date: Options vest over a one-year period commencing May 31, 2022 in 12 equal monthly installments. Read SEC document |
| May 24, 2022 Filed May 26, 2022 19:49 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantCommon Stock | 632 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001562180-22-004430 · primarydocument.xml · nonDerivative · entry 1 Pucci Paolo · CIK 0001436861 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,695.95 F1 · price: These shares of restricted stock units will vest in full on the first anniversary of the date of grant and will be distributable under the terms of the Deferred Compensation Plan for Outside Directors. Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 20:09 UTC | Replimune Group, Inc. REPL · Entity 4707 | GrantStock Option (right to buy) · Derivative | 16,500 | $0.00 Strike: $18.26 | $0.00 |
DisclosureSEC source: 0001104659-22-042749 · tm2211665-13_4seq1.xml · derivative · entry 1 Pucci Paolo · CIK 0001436861 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,500 Underlying: Common Stock · 16,500 shares Expires 2032-04-01 F1 · derivative.exercise_date: The shares underlying this option vest entirely on April 1, 2023. Read SEC document |
| November 17, 2021 Filed Nov 19, 2021 18:33 UTC | Trillium Therapeutics Inc. TRIL · Entity 133265 | Disposition to issuerStock Option (Right to Buy) · Derivative | 67,000 | $0.00 Strike: $15.50 | $0.00 |
DisclosureSEC source: 0001104659-21-141751 · tm2133436-1_4seq1.xml · derivative · entry 1 Pucci Paolo · CIK 0001436861 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 67,000 shares Expires 2030-11-15 F1 · derivative.exercise_date: On November 17, 2021 (the "Closing Date"), PF Argentum Acquisition ULC, an indirect wholly owned subsidiary of Pfizer, Inc. (the "Purchaser") acquired all of the outstanding common shares of Trillium Therapeutics Inc. (the "Issuer") under a plan of arrangement pursuant to the Canada Business Corporations Act (British Columbia) (the "Plan of Arrangement"), whereby Issuer became a wholly owned subsidiary of the Purchaser. At the Effective Time (the "Effective Time") of the Plan of Arrangement, all common shares and equity awards of the Issuer that were issued and outstanding immediately prior to the Effective Time were converted into the right to receive $18.50 per share in cash. Read SEC document |
| May 28, 2021 Filed Jun 2, 2021 20:10 UTC | Merus N.V. MRUS · Entity 70740 | GrantShare option (right to buy) · Derivative | 6,120 | $0.00 Strike: $21.15 | $0.00 |
DisclosureSEC source: 0000899243-21-021545 · doc4.xml · derivative · entry 1 Pucci Paolo · CIK 0001436861 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,120 Underlying: Common Shares · 6,120 shares Expires 2031-05-28 F1 · derivative.exercise_date: Options vest over a one-year period commencing May 28, 2021 in 12 equal monthly installments. Read SEC document |
| May 04, 2021 Filed May 6, 2021 23:29 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantCommon Stock | 577 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001562180-21-003310 · primarydocument.xml · nonDerivative · entry 1 Pucci Paolo · CIK 0001436861 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,063.95 F1 · price: These shares of restricted stock units will vest in full on the first anniversary of the date of grant and will be distributable under the terms of the Deferred Compensation Plan for Outside Directors. F2 · balance_after: Reflects additional shares purchased through dividend reinvestments based on most recent plan statement. Read SEC document |
| April 01, 2021 Filed Apr 6, 2021 00:14 UTC | Replimune Group, Inc. REPL · Entity 4707 | GrantStock Option (right to buy) · Derivative | 16,500 | $0.00 Strike: $31.58 | $0.00 |
DisclosureSEC source: 0001104659-21-046723 · tm2112099-5_4seq1.xml · derivative · entry 1 Pucci Paolo · CIK 0001436861 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,500 Underlying: Common Stock · 16,500 shares Expires 2031-04-01 F1 · derivative.exercise_date: The shares underlying this option vest entirely on April 1, 2022. Read SEC document |
| June 30, 2020 Filed Jul 2, 2020 20:00 UTC | Merus N.V. MRUS · Entity 70740 | GrantShare Option (right to buy) · Derivative | 17,262 | $0.00 Strike: $16.09 | $0.00 |
DisclosureSEC source: 0001209191-20-040207 · doc4.xml · derivative · entry 1 Pucci Paolo · CIK 0001436861 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,262 Underlying: Common Shares · 17,262 shares Expires 2030-06-30 F1 · derivative.exercise_date: Options vest over a three-year period commencing June 30, 2020. One-third vest after one year and in 24 equal monthly installments thereafter. Read SEC document |
| May 05, 2020 Filed May 7, 2020 22:06 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantCommon Stock | 975 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001562180-20-003465 · primarydocument.xml · nonDerivative · entry 1 Pucci Paolo · CIK 0001436861 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,469.9173 F1 · price: These shares of restricted stock units will vest in full on the first anniversary of the date of grant and will be distributable under the terms of the Deferred Compensation Plan for Outside Directors. F2 · balance_after: Reflects additional shares purchased through dividend reinvestments based on most recent plan statement. Read SEC document |
| April 01, 2020 Filed Apr 2, 2020 20:32 UTC | Replimune Group, Inc. REPL · Entity 4707 | GrantStock Option (right to buy) · Derivative | 33,000 | $0.00 Strike: $9.78 | $0.00 |
DisclosureSEC source: 0001104659-20-042501 · a4.xml · derivative · entry 1 Pucci Paolo · CIK 0001436861 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,000 Underlying: Common Stock · 33,000 shares Expires 2030-04-01 F1 · derivative.exercise_date: 25% of the shares underlying this stock option vest on April 1, 2021, and the remainder of the shares underlying this stock option vest in 24 approximately equal monthly installments thereafter. Read SEC document |
| January 16, 2020 Filed Jan 16, 2020 15:56 UTC | ARQULE INC ARQL · Entity 11927 | Disposition to issuerStock Option (Right to Buy) · Derivative | 305,000 | Not disclosed Strike: $2.57 | Not disclosed |
DisclosureSEC source: 0001104659-20-004720 · tm203607d6_4.xml · derivative · entry 14 Pucci Paolo · CIK 0001436861 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 305,000 shares Expires 2024-01-22 F2 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. Read SEC document |
| January 16, 2020 Filed Jan 16, 2020 15:56 UTC | ARQULE INC ARQL · Entity 11927 | Disposition to issuerStock Option (Right to Buy) · Derivative | 285,000 | Not disclosed Strike: $2.51 | Not disclosed |
DisclosureSEC source: 0001104659-20-004720 · tm203607d6_4.xml · derivative · entry 13 Pucci Paolo · CIK 0001436861 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 285,000 shares Expires 2023-01-14 F2 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. Read SEC document |
| January 16, 2020 Filed Jan 16, 2020 15:56 UTC | ARQULE INC ARQL · Entity 11927 | Disposition to issuerStock Option (Right to Buy) · Derivative | 7,578 | Not disclosed Strike: $7.95 | Not disclosed |
DisclosureSEC source: 0001104659-20-004720 · tm203607d6_4.xml · derivative · entry 12 Pucci Paolo · CIK 0001436861 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,578 shares Expires 2022-02-01 F2 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. Read SEC document |
| January 16, 2020 Filed Jan 16, 2020 15:56 UTC | ARQULE INC ARQL · Entity 11927 | Disposition to issuerStock Option (Right to Buy) · Derivative | 14,925 | Not disclosed Strike: $6.70 | Not disclosed |
DisclosureSEC source: 0001104659-20-004720 · tm203607d6_4.xml · derivative · entry 11 Pucci Paolo · CIK 0001436861 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,925 shares Expires 2021-01-24 F2 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. Read SEC document |
| January 16, 2020 Filed Jan 16, 2020 15:56 UTC | ARQULE INC ARQL · Entity 11927 | Disposition to issuerStock Option (Right to Buy) · Derivative | 100,000 | Not disclosed Strike: $4.14 | Not disclosed |
DisclosureSEC source: 0001104659-20-004720 · tm203607d6_4.xml · derivative · entry 10 Pucci Paolo · CIK 0001436861 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,000 shares Expires 2020-07-15 F2 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. Read SEC document |
| January 16, 2020 Filed Jan 16, 2020 15:56 UTC | ARQULE INC ARQL · Entity 11927 | Disposition to issuerStock Option (Right to Buy) · Derivative | 650,850 | Not disclosed Strike: $3.68 | Not disclosed |
DisclosureSEC source: 0001104659-20-004720 · tm203607d6_4.xml · derivative · entry 9 Pucci Paolo · CIK 0001436861 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 650,850 shares Expires 2029-01-15 F2 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. Read SEC document |
| January 16, 2020 Filed Jan 16, 2020 15:56 UTC | ARQULE INC ARQL · Entity 11927 | Disposition to issuerStock Option (Right to Buy) · Derivative | 150,000 | Not disclosed Strike: $5.48 | Not disclosed |
DisclosureSEC source: 0001104659-20-004720 · tm203607d6_4.xml · derivative · entry 8 Pucci Paolo · CIK 0001436861 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 150,000 shares Expires 2028-07-23 F2 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. Read SEC document |
| January 16, 2020 Filed Jan 16, 2020 15:56 UTC | ARQULE INC ARQL · Entity 11927 | Disposition to issuerStock Option (Right to Buy) · Derivative | 80,000 | Not disclosed Strike: $2.48 | Not disclosed |
DisclosureSEC source: 0001104659-20-004720 · tm203607d6_4.xml · derivative · entry 7 Pucci Paolo · CIK 0001436861 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 80,000 shares Expires 2028-05-08 F2 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. Read SEC document |
| January 16, 2020 Filed Jan 16, 2020 15:56 UTC | ARQULE INC ARQL · Entity 11927 | Disposition to issuerStock Option (Right to Buy) · Derivative | 249,000 | Not disclosed Strike: $1.75 | Not disclosed |
DisclosureSEC source: 0001104659-20-004720 · tm203607d6_4.xml · derivative · entry 6 Pucci Paolo · CIK 0001436861 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 249,000 shares Expires 2028-01-16 F2 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. Read SEC document |
| January 16, 2020 Filed Jan 16, 2020 15:56 UTC | ARQULE INC ARQL · Entity 11927 | Disposition to issuerStock Option (Right to Buy) · Derivative | 600,000 | Not disclosed Strike: $0.95 | Not disclosed |
DisclosureSEC source: 0001104659-20-004720 · tm203607d6_4.xml · derivative · entry 5 Pucci Paolo · CIK 0001436861 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 600,000 shares Expires 2027-04-04 F2 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. Read SEC document |
| January 16, 2020 Filed Jan 16, 2020 15:56 UTC | ARQULE INC ARQL · Entity 11927 | Disposition to issuerStock Option (Right to Buy) · Derivative | 300,000 | Not disclosed Strike: $1.53 | Not disclosed |
DisclosureSEC source: 0001104659-20-004720 · tm203607d6_4.xml · derivative · entry 4 Pucci Paolo · CIK 0001436861 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 300,000 shares Expires 2027-01-17 F2 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. Read SEC document |
| January 16, 2020 Filed Jan 16, 2020 15:56 UTC | ARQULE INC ARQL · Entity 11927 | Disposition to issuerStock Option (Right to Buy) · Derivative | 120,000 | Not disclosed Strike: $1.79 | Not disclosed |
DisclosureSEC source: 0001104659-20-004720 · tm203607d6_4.xml · derivative · entry 3 Pucci Paolo · CIK 0001436861 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 120,000 shares Expires 2026-01-19 F2 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. Read SEC document |
| January 16, 2020 Filed Jan 16, 2020 15:56 UTC | ARQULE INC ARQL · Entity 11927 | Disposition to issuerStock Option (Right to Buy) · Derivative | 242,502 | Not disclosed Strike: $1.16 | Not disclosed |
DisclosureSEC source: 0001104659-20-004720 · tm203607d6_4.xml · derivative · entry 2 Pucci Paolo · CIK 0001436861 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 242,502 shares Expires 2025-01-20 F2 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. Read SEC document |
| January 16, 2020 Filed Jan 16, 2020 15:56 UTC | ARQULE INC ARQL · Entity 11927 | OtherCommon Stock | 1,235,782 | $20.00 | $24,715,640.00 |
DisclosureSEC source: 0001104659-20-004720 · tm203607d6_4.xml · nonDerivative · entry 1 Pucci Paolo · CIK 0001436861 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: On December 6, 2019, ArQule, Inc. (the "Company") entered into an Agreement and Plan of Merger (as amended, supplemented or otherwise modified from time to time, the "Merger Agreement") with Merck Sharpe & Dohme Corp. ("MSD") and Argon Merger Sub, Inc., a wholly-owned subsidiary of MSD ("Merger Sub"), pursuant to which MSD acquired the Company by a tender offer for all shares of Company common stock (the "Offer") and a subsequent merger (the "Merger"), each of which became effective on January 16, 2020. Pursuant to the Merger Agreement, (i) Merger Sub purchased all shares of Company common stock that were validly tendered pursuant to the Offer for a cash payment equal to $20.00 per share (the "Offer Price") and (ii) all shares of Company common stock outstanding immediately prior to the effective time of the Merger (the "Effective Time"), were cancelled and converted automatically into the right to receive the Offer Price. Read SEC document |
| December 18, 2019 Filed Dec 20, 2019 16:09 UTC | ARQULE INC ARQL · Entity 11927 | Exercise / conversionStock Options (Right to Buy) · Derivative | 360,000 | $0.00 Strike: $1.79 | $0.00 |
DisclosureSEC source: 0001104659-19-074986 · tm1926797d3_4.xml · derivative · entry 9 Pucci Paolo · CIK 0001436861 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 360,000 shares Expires 2026-01-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 18, 2019 Filed Dec 20, 2019 16:09 UTC | ARQULE INC ARQL · Entity 11927 | Exercise / conversionStock Options (Right to Buy) · Derivative | 285,075 | $0.00 Strike: $6.70 | $0.00 |
DisclosureSEC source: 0001104659-19-074986 · tm1926797d3_4.xml · derivative · entry 8 Pucci Paolo · CIK 0001436861 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 285,075 shares Expires 2021-01-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 18, 2019 Filed Dec 20, 2019 16:09 UTC | ARQULE INC ARQL · Entity 11927 | Exercise / conversionStock Options (Right to Buy) · Derivative | 302,422 | $0.00 Strike: $7.95 | $0.00 |
DisclosureSEC source: 0001104659-19-074986 · tm1926797d3_4.xml · derivative · entry 7 Pucci Paolo · CIK 0001436861 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 302,422 shares Expires 2022-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 18, 2019 Filed Dec 20, 2019 16:09 UTC | ARQULE INC ARQL · Entity 11927 | Exercise / conversionStock Options (Right to Buy) · Derivative | 225,000 | $0.00 Strike: $3.42 | $0.00 |
DisclosureSEC source: 0001104659-19-074986 · tm1926797d3_4.xml · derivative · entry 6 Pucci Paolo · CIK 0001436861 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 225,000 shares Expires 2020-01-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 18, 2019 Filed Dec 20, 2019 16:09 UTC | ARQULE INC ARQL · Entity 11927 | Tax withholdingCommon Stock | 646,639 | $20.11 | $13,003,910.29 |
DisclosureSEC source: 0001104659-19-074986 · tm1926797d3_4.xml · nonDerivative · entry 5 Pucci Paolo · CIK 0001436861 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,235,245 F1 · balance_after: The Reporting Person satisfied the exercise price and applicable tax withholding by electing to have the Company retain shares otherwise issuable upon exercise of the options. No shares were sold into the market as part of this transaction, and the Reporting Person continues to hold the net shares realized from the option exercise. Read SEC document |
| December 18, 2019 Filed Dec 20, 2019 16:09 UTC | ARQULE INC ARQL · Entity 11927 | Exercise / conversionCommon Stock | 360,000 | $1.79 | $644,400.00 |
DisclosureSEC source: 0001104659-19-074986 · tm1926797d3_4.xml · nonDerivative · entry 4 Pucci Paolo · CIK 0001436861 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,881,884 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 18, 2019 Filed Dec 20, 2019 16:09 UTC | ARQULE INC ARQL · Entity 11927 | Exercise / conversionCommon Stock | 285,075 | $6.70 | $1,910,002.50 |
DisclosureSEC source: 0001104659-19-074986 · tm1926797d3_4.xml · nonDerivative · entry 3 Pucci Paolo · CIK 0001436861 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,521,884 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 18, 2019 Filed Dec 20, 2019 16:09 UTC | ARQULE INC ARQL · Entity 11927 | Exercise / conversionCommon Stock | 302,422 | $7.95 | $2,404,254.90 |
DisclosureSEC source: 0001104659-19-074986 · tm1926797d3_4.xml · nonDerivative · entry 2 Pucci Paolo · CIK 0001436861 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,236,809 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 18, 2019 Filed Dec 20, 2019 16:09 UTC | ARQULE INC ARQL · Entity 11927 | Exercise / conversionCommon Stock | 225,000 | $3.42 | $769,500.00 |
DisclosureSEC source: 0001104659-19-074986 · tm1926797d3_4.xml · nonDerivative · entry 1 Pucci Paolo · CIK 0001436861 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 934,387 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.